Am J Transplant, Volume 22, Suppl 3 Archives - Page 19 of 190 - ATC Abstracts

2022 American Transplant Congress
The Role Of Ferroptosis In Modulating Ischemia Reperfusion Injury(IRI) Gene Expression In Marginal Donor Livers(MDLS) Using The Novel Protect Normothermic Perfusion Pump
M. D. Nazzal¹, K. Kurashima², J. Bettag², A. Chen², S. Bruno², A. Nagarapu², J. Van Nispen¹, J. Krebs², J. Teckman², D. Carpenter³, D. Hermelin³, C. Varma¹, A. Jain²
¹Surgery, Saint Louis University, Saint Louis, MO, ²Pediatrics, Saint Louis University, Saint Louis, MO, ³Pathology, Saint Louis University, Saint Louis, MO
*Purpose: Severe IRI can impair liver allograft when using MDLs and accounts for high discard rates. We tested iron chelators to reduce ferroptosis and IRI.…
2022 American Transplant Congress
Comparing The Immunologic Responses Between Kidney Transplant Recipients Receiving Standard Immunosuppression And CNI Reduction After Two Doses Of ChAdOx-1 And A Booster Dose BNT162b2
S. Phirom¹, T. Kitrungphaiboon², W. Jantarabenjakul², Y. Avihingsanon², W. Prasithsirikul³, J. Vanichanan⁴, P. Hansasuta⁵, N. Townamchai⁶
¹Nephrology division, Department of medicine, King Chulalongkorn Memorial Hospital, Bangkok, Thailand, ²King Chulalongkorn Memorial Hospital, Bangkok, Thailand, ³Bamrasnaradura infectious disease institute, Bangkok, Thailand, ⁴Infectious diseases, Department of medicine, King Chulalongkorn Memorial Hospital, Bangkok, Thailand, ⁵Department of Microbiology, King Chulalongkorn Memorial Hospital, Bangkok, Thailand, ⁶Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, Thailand
*Purpose: Immunosuppression can impair immunological responses after vaccination in kidney transplant recipients (KTR). However, little is known about the effect of the booster dose of…
2022 American Transplant Congress
Reproductive Counseling in Kidney Transplant: Patient Needs and Current Practices
S. Rajagopal¹, J. Ritchie², D. Seidman³, Y. Srisengfa⁴, E. R. Perito⁵, D. Adey⁶, M. Sarkar⁷
¹Internal Medicine, Brookdale University Hospital, Brooklyn, NY, ²Obstetrics and Gynecology, St Luke's University Health Network, Bethlehem, PA, ³Obstetrics and Gynecology, University of California San Francisco, San Francisco, CA, ⁴University of California San Francisco, San Francisco, CA, ⁵Pediatric GI/Hepatology, University of California San Francisco, San Francisco, CA, ⁶Nephrology, University of California San Francisco, San Francisco, CA, ⁷GI/Hepatology, University of California San Francisco, San Francisco, CA
*Purpose: Nearly 20% of female kidney transplant (KT) recipients are reproductive-aged. Early/unplanned pregnancies post-KT increase maternal and fetal risks, though data on reproductive counseling in…
2022 American Transplant Congress
Induction Immunosuppression Does Not Worsen Tumor Recurrence After Liver Transplantation for T2 Hepatocellular Carcinoma and May Allow for Decreased Mortality
C. Durkin¹, T. Bittermann¹, D. E. Schaubel²
¹Gastroenterology, University of Pennsylvania, Philadelphia, PA, ²Biostatistics, University of Pennsylvania, Philadelphia, PA
*Purpose: Prior studies have suggested that induction therapy leads to worse outcomes after liver transplantation (LT) for hepatocellular carcinoma (HCC). This study evaluated the impact…
2022 American Transplant Congress
Maribavir (MBV) versus Investigator-Assigned Therapy (IAT) for Refractory Cytomegalovirus (CMV) Infection (with or without Resistance) in Solid Organ Transplant (SOT) Recipients: Subgroup Safety Analysis of a Phase 3 Study
R. M. La Hoz¹, D. Florescu², D. Kumar³, F. Saliba⁴, J. Gu⁵, A. Sundberg⁵
¹Univ. Texas Southwestern Medical Center, Dallas, TX, ²Univ. Nebraska Medical Center, Omaha, NE, ³Univ. Health Network, Toronto, ON, Canada, ⁴Univ. Paris Saclay, Paris, France, ⁵Takeda Development Center Americas, Inc., Lexington, MA
*Purpose: In a Phase 3 study of MBV vs IAT (val/ganciclovir, foscarnet, or cidofovir) for refractory CMV infection (with/without resistance; R/R) in hematopoietic cell transplant…
2022 American Transplant Congress
Association of Native Kidney Disease with De Novo Cancer Development After Kidney Transplant
Y. Caliskan¹, D. Axelrod², R. Li¹, W. Cheungpasitporn³, M. Schnitzler¹, M. McAdams DeMarco⁴, J. Ahn⁴, T. Alhamad⁵, H. Randall¹, S. Bae⁴, D. Segev⁴, K. L. Lentine¹
¹Saint Louis University, Saint Louis, MO, ²University of Iowa, Iowa City, IA, ³Mayo Clinic, Rochester, MN, ⁴John Hopkins University, Baltimore, MD, ⁵Washington University in Saint Louis, Saint Louis, MO
*Purpose: Primary glomerulonephritis (GN) and congenital anomalies of the kidney and urinary tract (CAKUT) have been shown to be associated with cancer development in the…
2022 American Transplant Congress
Histocompatibility Findings in the First Xenotransplants from a Pig to Deceased Human Recipient
M. Mangiola, V. Tatapudi, J. Stern, Z. Stewart Lewis, B. Lonze, N. Ali, R. Montgomery
Transplant Institute, NYU Langone Transplant Institute, New York, NY
*Purpose: Humans lack α-1,3-Gal (α-gal) epitopes, and naturally occurring α-gal antibodies (Abs) cause hyperacute rejection of porcine xenografts. We conducted 2 successful xenotransplants in brain-dead…
2022 American Transplant Congress
Donor Organ Utilization And Transplantation Outcomes In Donation After Circulatory Death Using Thoracoabdominal Normothermic Regional Perfusion
M. Urban, S. Merani, N. W. Markin, A. Castleberry, J. Um
University of Nebraska Medical Center, Omaha, NE
*Purpose: Evidence suggests that in-situ reperfusion of abdominal organs with normothermic oxygenated blood in donation after circulatory death (DCD) provides superior post-transplantation outcomes in comparison…
2022 American Transplant Congress
Pre-Emptive Rituximab to Prevent Post Transplant Lymphoproliferative Disorder (PTLD) in Pediatric Kidney Transplant Recipients with EBV DNAemia: A Case Series from the Pediatric Nephrology Research Consortium (PNRC)
I. Ashoor¹, S. Ranabothu², S. Al-Akash³, A. Moudgil⁴, Y. Shi⁴, S. Kizilbash⁵, D. Puliyanda⁶, V. Dharnidharka⁷
¹LSU Health Sciences Center New Orleans, New Orleans, LA, ²Arkansas Children's Hospital, Little Rock, AR, ³Driscoll Children's Hospital, Corpus Christie, TX, ⁴Children's National Medical Center, Washington, DC, ⁵University of Minnesota Medical Center, Minneapolis, MN, ⁶Cedars-Sinai Medical Center, Los Angeles, CA, ⁷Washington University in St. Louis, St Louis, MO
*Purpose: The use of Rituximab (RTX) to prevent PTLD in patients with EBV DNAemia is an established strategy in hematopoietic stem cell transplants, but with…
2022 American Transplant Congress
Three-Way Comparison of Central DSA, %dd-cf DNA, and Molecular Biopsy Findings in the Trifecta Study
P. F. Halloran¹, L. G. Hidalgo², Z. Demko³, A. Prewett³, J. Reeve¹, C. Lawrence⁴, D. Lowe⁴, P. Billings³, .. and the Trifecta Investigators⁵
¹Alberta Transplant Applied Genomics Centre, Edmonton AB, AB, Canada, ²University of Wisconsin, Madison, WI, ³Natera Inc., San Carlos, CA, ⁴One Lambda Inc., West Hills, CA, ⁵., ., AB, Canada
*Purpose: Trifecta (ClinicalTrials.gov #NCT04239703) is a prospective, IRB-approved, consented study of the relationships among three central tests in kidney transplant indication biopsies: molecular biopsy diagnoses…